Sugi Predict

Sugi Predict / Compounds / SCHEMBL3680146

SCHEMBL3680146

SCHEMBL3680146

COC(=O)C=Cc1ccc(F)c(Br)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 1/20 0.58
▸ APP P05067 1/20 0.58
▸ MAOB P27338 5/20 0.56
▸ MAOA P21397 4/20 0.56
▸ PTPN1 P18031 1/20 0.55
▸ CA12 O43570 1/20 0.54
▸ CA1 P00915 1/20 0.54
▸ CA2 P00918 1/20 0.54
▸ TYR P14679 1/20 0.54
▸ CA7 P43166 1/20 0.54
▸ CA9 Q16790 1/20 0.54
▸ CA14 Q9ULX7 1/20 0.54
▸ EPHX2 P34913 1/20 0.54
▸ KDM4E B2RXH2 3/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ JAK2 O60674 1/20 0.52
▸ GAA P10253 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ HTT P42858 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3680144 1.00 TTR (0.58) TTRAPPMAOBMAOAPTPN1
SCHEMBL28735753 0.88 TTR (0.58) TTRAPPMAOBMAOAPTPN1
SCHEMBL31560386 0.85 TTR (0.63) TTRAPPPTPN1CA12CA1
SCHEMBL6960198 0.85 TTR (0.63) TTRAPPPTPN1CA12CA1
SCHEMBL6960203 0.85 TTR (0.63) TTRAPPPTPN1CA12CA1
SCHEMBL23927509 0.84 TTR (0.61) TTRAPPMAOBPTPN1CA12
SCHEMBL22273094 0.84 TTR (0.61) TTRAPPMAOBPTPN1CA12
SCHEMBL1907799 0.84 TTR (0.61) TTRAPPMAOBMAOACA12
SCHEMBL1932621 0.84 TTR (0.61) TTRAPPMAOBMAOACA12
SCHEMBL2847487 0.83 TTR (0.59) TTRAPPPTPN1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509446-B2 FYN and VEGFR2 kinase inhibitors ROTTAPHARM BIOTECH S.R.L. (IT) 2025-12-30 — — US disclosed
EP-4073057-B1 NEW FYN AND VEGFR2 KINASE INHIBITORS Rottapharm Biotech Srl (IT) 2023-11-29 — — EP disclosed
US-20230061118-A1 NEW FYN AND VEGFR2 KINASE INHIBITORS ROTTAPHARM BIOTECH S.R.L. (IT) 2023-03-02 — — US disclosed
EP-4073057-A1 NEW FYN AND VEGFR2 KINASE INHIBITORS Rottapharm Biotech S.r.l. (IT) 2022-10-19 — — EP disclosed
WO-2021115560-A1 NEW FYN AND VEGFR2 KINASE INHIBITORS ROTTAPHARM BIOTECH S.R.L. (IT) 2021-06-17 — — WO disclosed
WO-2021116005-A1 NEW FYN AND VEGFR2 KINASE INHIBITORS ROTTAPHARM BIOTECH S.R.L. (IT) 2021-06-17 — — WO disclosed
US-20100048893-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-02-25 — — US disclosed
EP-2134703-A1 AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS Neuromed Pharmaceuticals, Ltd. (CA) 2009-12-23 — — EP disclosed
US-20090062530-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-03-05 — — US disclosed
US-7470807-B2 Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate ASAHI KASEI PHARMA CORPORATION (JP) 2008-12-30 — — US disclosed
US-20080227823-A1 (E)-4-(3-(3-bromo-4-fluorophenyl)acrylamido)-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)piperidine-4-carboxamide; ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity ZALICUS PHARMACEUTICALS LTD. (CA) 2008-09-18 — — US disclosed
WO-2008110008-A1 AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS NEUROMED PHARMACEUTICALS LTD. (CA) 2008-09-18 — — WO disclosed
US-20070213333-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHAMA CORPORATION (JP) 2007-09-13 — — US disclosed
CN-101031539-A Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHAMA CORP (JP) 2007-09-05 — — CN disclosed
EP-1660427-A4 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2006-12-20 — — EP disclosed
EP-1660427-A1 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2006-05-31 — — EP disclosed
WO-2005016862-A1 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORPORATION (JP) 2005-02-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509446-B2 FYN and VEGFR2 kinase inhibitors FYN, LCK, LYN TTR 2202/4885APP 2099/4885MAOB 1943/4885
US-20080227823-A1 (E)-4-(3-(3-bromo-4-fluorophenyl)acrylamido)-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)piperidine-4-carboxamide; ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity CACNA1G, KCNN4, CACNA1E TTR 3102/4885APP 672/4885MAOB 582/4885
US-20100048893-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 TTR 3315/4885APP 3879/4885MAOB 886/4885
US-20070213333-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 TTR 3315/4885APP 3879/4885MAOB 886/4885
US-20230061118-A1 NEW FYN AND VEGFR2 KINASE INHIBITORS FYN, SRC, PTK2B TTR 1669/4885APP 1892/4885MAOB 957/4885
US-20090062530-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 TTR 3315/4885APP 3879/4885MAOB 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.